“…[88] From a clinical perspective, many TRPV3 gain-of-function mutations (e.g., G573S, G573C, G573A, W692G, W692C, W692S, W521S, G568C, G568D, G568V, R416Q, R416W, Q580P, L655P, M672I, L673F, A675T, and L694P) are seen in human patients with Olmsted syndrome (OS), a hyperkeratotic skin disease. [89][90][91] Most of these variant TRPV3 channels exhibit differential elevation in basal opening probabilities and cytotoxicity. [89,92] Correspondingly, a significantly higher proportion of apoptotic keratinocytes were detected in lesions from patients with OS, suggesting that hyperkeratosis in these patients may be due to increased keratinocyte apoptosis when overactive TRPV3 channel variants are expressed.…”